Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study

被引:431
作者
Cheung, AK
Sarnak, MJ
Yan, GF
Berkoben, M
Heyka, R
Kaufman, A
Lewis, J
Rocco, M
Toto, R
Windus, D
Ornt, D
Levey, AS
机构
[1] Univ Utah, Salt Lake City, UT 84112 USA
[2] Vet Affairs Salt Lake City Healthcare Syst, Salt Lake City, UT USA
[3] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[4] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[5] Duke Univ, Durham, NC USA
[6] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
[7] Vanderbilt Univ, Nashville, TN USA
[8] Wake Forest Univ, Winston Salem, NC 27109 USA
[9] Univ Texas, SW Med Sch, Dallas, TX 75230 USA
[10] Washington Univ, St Louis, MO USA
[11] Univ Rochester, Rochester, NY USA
关键词
hemodialysis; cardiac disease; mortality; outcome; high flux; randomized trial;
D O I
10.1111/j.1523-1755.2004.00657.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Cardiac disease is a common cause of death in chronic hemodialysis patients. A subanalysis of the data on cardiac diseases in the Hemodialysis (HEMO) Study was performed. The specific objectives were: (1) to analyze the prevalence of cardiac disease at baseline; (2) to characterize the incidence of various types of cardiac events during follow-up; (3) to examine the association of cardiac events during follow-up with baseline cardiac diseases; and (4) to examine the effect of dose and flux interventions on various types of cardiac events. Methods. The HEMO Study is a randomized multi-center trial on 1846 chronic hemodialysis patients at 15 clinical centers comprising 72 dialysis units. The scheduled maximum follow-up duration was 0.9 to 6.6 years, with the mean actual follow-up of 2.84 years. The interventions were standard-dose versus high-dose and low-flux versus high-flux hemodialysis in a 2 x 2 factorial design. Results. At baseline, 80% of patients had cardiac diseases, including ischemic heart disease (IHD) (39%), congestive heart failure (40%), arrhythmia (31%), and other heart diseases (63%). There were a total of 1685 cardiac hospitalizations, with angina and acute myocardial infarction accounting for 42.7% of these hospitalizations. There were 343 cardiac deaths during follow-up, accounting for 39.4% of all deaths. IHD was implicated in 61.5% of the cardiac deaths. Any cardiac disease at baseline was highly predictive of cardiac death during follow-up [relative risk (RR) 2.57; 95% CI 1.73-3.83]. There were no significant effects of dose or flux assignments on the primary outcome of all-cause mortality or the main secondary cardiac composite outcome of first cardiac hospitalization or all-cause mortality. Assignment to high-flux dialysis was, however, associated with decreased cardiac mortality and the composite outcome of first cardiac hospitalization or death from cardiac causes. Conclusion. The HEMO Study identified IHD to be a major cause of cardiac hospitalizations and cardiac deaths. Future strategies for the prevention of cardiac diseases in the maintenance hemodialysis population should focus on this entity. Although high-flux dialysis did not reduce all-cause mortality, it might improve cardiac outcomes. This hypothesis needs to be further examined.
引用
收藏
页码:2380 / 2389
页数:10
相关论文
共 24 条
[1]   Effects of high-flux Hemodialysis on clinical outcomes: Results of the HEMO study [J].
Cheung, AK ;
Levin, NW ;
Greene, T ;
Agodoa, L ;
Bailey, J ;
Beck, G ;
Clark, W ;
Levey, AS ;
Leypoldt, JK ;
Ornt, DB ;
Rocco, MV ;
Schulman, G ;
Schwab, S ;
Teehan, B ;
Eknoyan, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (12) :3251-3263
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]  
Eknoyan G, 1997, KIDNEY INT, V52, P1395
[4]   Effect of dialysis dose and membrane flux in maintenance hemodialysis. [J].
Eknoyan, G ;
Beck, GJ ;
Cheung, AK ;
Daugirdas, JT ;
Greene, T ;
Kusek, JW ;
Allon, M ;
Bailey, J ;
Delmez, JA ;
Depner, TA ;
Dwyer, JT ;
Levey, AS ;
Levin, NW ;
Milford, E ;
Ornt, DB ;
Rocco, MV ;
Schulman, G ;
Schwab, SJ ;
Teehan, BP ;
Toto, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2010-2019
[5]   The hemodialysis (HEMO) study: Rationale for selection of interventions [J].
Eknoyan, G ;
Levey, AS ;
Beck, GJ ;
Agodoa, LY ;
Daugirdas, JT ;
Kusek, JW ;
Levin, NW ;
Schulman, G .
SEMINARS IN DIALYSIS, 1996, 9 (01) :24-33
[6]  
Foley R N, 1997, Adv Ren Replace Ther, V4, P234
[7]  
Foley RN, 1998, J AM SOC NEPHROL, V9, P267
[8]   Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients [J].
Fung, F ;
Sherrard, DJ ;
Gillen, DL ;
Wong, C ;
Kestenbaum, B ;
Seliger, S ;
Ball, A ;
Stehman-Breen, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :307-314
[9]   Design and statistical issues of the Hemodialysis (HEMO) Study [J].
Greene, T ;
Beck, GJ ;
Gassman, JJ ;
Gotch, FA ;
Kusek, JW ;
Levey, AS ;
Levin, NW ;
Schulman, G ;
Eknoyan, G .
CONTROLLED CLINICAL TRIALS, 2000, 21 (05) :502-525
[10]   CONGESTIVE-HEART-FAILURE IN DIALYSIS PATIENTS - PREVALENCE, INCIDENCE, PROGNOSIS AND RISK-FACTORS [J].
HARNETT, JD ;
FOLEY, RN ;
KENT, GM ;
BARRE, PE ;
MURRAY, D ;
PARFREY, PS .
KIDNEY INTERNATIONAL, 1995, 47 (03) :884-890